Advances in Infectious Diseases
Vol.6 No.1(2016), Paper ID 64702, 8
pages
DOI:10.4236/aid.2016.61002
Efficacy of 2LPAPI®, a Micro-Immunotherapy Drug, in Patients with High-Risk Papillomavirus Genital Infection
Gilles Thomas, Hélène Cluzel, Jacqueline Lafon, Jacques Bruhwyler, Béatrice Lejeune
Private Gynecology Practice, Perpignan, France
Private Gynecology Practice, Perpignan, France
Labo’Life France sarl, Pescalis, Les Magny, France
ECSOR sa/nv, Blanmont, Belgium
Labo’Life Belgium sprl, Les Isnes, Belgium
Copyright © 2016 Gilles Thomas, Hélène Cluzel, Jacqueline Lafon, Jacques Bruhwyler, Béatrice Lejeune et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Thomas, G. , Cluzel, H. , Lafon, J. , Bruhwyler, J. and Lejeune, B. (2016) Efficacy of 2LPAPI
®, a Micro-Immunotherapy Drug, in Patients with High-Risk Papillomavirus Genital Infection.
Advances in Infectious Diseases,
6, 7-14. doi:
10.4236/aid.2016.61002.